第二阶段

我们是谁

  • 12 月 22, 2023
    Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
  • 12 月 22, 2023
    CA102N 联合 TAS-102 与贝伐珠单抗联合 TAS-102 治疗复发性和/或难治性转移性结直肠癌受试者的 2 期研究比较
  • 12 月 22, 2023
    Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
  • 12 月 22, 2023
    针对转移性结直肠癌受试者的 CNA3103（LGR5 靶向自体 CAR-T 细胞）研究
  • 12 月 22, 2023
    RC48-ADC 联合贝伐单抗治疗 HER2 阳性晚期结直肠癌
  • 12 月 18, 2023
    Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
  • 12 月 18, 2023
    Immunotherapy for Third Line Metastatic Colorectal Cancer
  • 10 月 31, 2023
    无病变证据 (NED) 的 IV 期结直肠癌患者的 Durvalumab 加瑞戈非尼辅助治疗与未治疗对照组对比：VIVA 试验
  • 10 月 17, 2023
    Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
  • 8 月 31, 2023
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors